PDS Biotechnology (NASDAQ:PDSB) Issues Quarterly Earnings Results

PDS Biotechnology (NASDAQ:PDSB) announced its quarterly earnings results on Friday. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02), FiscalAI reports.

PDS Biotechnology Stock Down 11.0%

Shares of PDSB traded down $0.11 on Friday, reaching $0.87. The company’s stock had a trading volume of 5,925,025 shares, compared to its average volume of 8,144,117. The company has a current ratio of 0.57, a quick ratio of 0.57 and a debt-to-equity ratio of 2.73. PDS Biotechnology has a twelve month low of $0.20 and a twelve month high of $1.79. The stock has a market capitalization of $48.84 million, a PE ratio of -1.36 and a beta of 1.16. The firm has a fifty day moving average of $0.97 and a 200-day moving average of $0.84.

Wall Street Analyst Weigh In

PDSB has been the subject of several recent research reports. HC Wainwright restated a “buy” rating on shares of PDS Biotechnology in a report on Wednesday, August 26th. Wall Street Zen upgraded PDS Biotechnology from a “sell” rating to a “hold” rating in a report on Monday, October 5th. B. Riley Financial reiterated a “buy” rating and issued a $4.00 target price (up from $3.00) on shares of PDS Biotechnology in a report on Thursday, October 29th. Finally, Weiss Ratings raised shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 28th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, PDS Biotechnology currently has a consensus rating of “Hold” and a consensus target price of $9.50.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company’s research is based primarily on its Versamune platform, a proprietary technology designed to stimulate targeted immune responses, including the activation of cancer-fighting T cells and natural killer cells. Its lead investigational product, PDS0101, is an immunotherapy candidate designed to target human papillomavirus type 16 (HPV16), a viral strain associated with several cancers.